FDA 483 - ECI Pharmaceuticals, LLC - January 27, 2023

ECI Pharmaceuticals, LLC in Ft Lauderdale, FL, was inspected regarding its post-marketing adverse drug experience reporting. The inspection revealed significant deficiencies in written procedures for surveillance, evaluation, and electronic submission of adverse drug experience reports. Additionally, the firm failed to submit required annual reports and periodic adverse drug experience reports for an active NDA.